PDL Biopharma Overview

  • Founded
  • 1986
Founded
  • Status
  • Public
  • Employees
  • 133
Employees
  • Investments
  • 8
  • Share Price
  • $2.43
  • (As of Monday Closing)

PDL Biopharma General Information

Description

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Contact Information

Website
www.pdl.com
Formerly Known As
Protein Design Labs, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Medical Supplies
Other Industries
Biotechnology
Primary Office
  • 932 Southwood Boulevard
  • Incline Village, NV 89451
  • United States
+1 (775) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PDL Biopharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.43 $2.63 $2.05 - $3.68 $282M 114M 348.56 -$1.32

PDL Biopharma Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 226,249 208,759 155,827 157,732
Revenue 55,371 30,706 32,028 320,060
EBITDA (110,440) (57,793) (35,807) 230,144
Net Income (154,366) (70,411) (68,859) 110,748
Total Assets 520,656 717,206 963,736 1,243,123
Total Debt 13,507 37,950 135,344 254,181
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PDL Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PDL Biopharma‘s full profile, request access.

Request a free trial

PDL Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the
Medical Supplies
Incline Village, NV
133 As of 2019
000.00
00000000 000.00

00000000

ptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proid
000000000000000
Mumbai, India
0000 As of 0000
000000000

00000000

lamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
000000000000000
Hyderabad, India
00000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PDL Biopharma Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Wockhardt Corporation Mumbai, India 0000 000000000
000000000 000000 Corporation Hyderabad, India 00000 00000 000000000 00000
0000 0000000000000 Corporate Backed or Acquired Petach Tikva, Israel 00000 00000 00000000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

PDL Biopharma Patents

PDL Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2792749-A4 Method for highly expressing recombinant protein of engineering bacteria and use thereof Granted 25-Nov-2011 0000000000 0
JP-5980342-B2 Method for expressing recombinant protein of genetically modified bacteria with high efficiency and method for preparing recombinant polypeptide using the same Expired - Fee Related 25-Nov-2011 0000000000
EP-2792749-B1 Method for highly expressing recombinant protein of engineering bacteria and use thereof Active 25-Nov-2011 0000000000
AU-2012342993-B2 Method for highly expressing recombinant protein of engineering bacteria and use thereof Ceased 25-Nov-2011 0000000000 0
JP-2014533511-A Method for expressing recombinant protein of genetically modified bacteria with high efficiency and method for preparing recombinant polypeptide using the same Granted 25-Nov-2011 C07K14/001 0

PDL Biopharma Executive Team (13)

Name Title Board Seat Contact Info
Ed Imbrogno Vice President & Chief Financial Officer
Christopher Stone JD Vice President, General Counsel & Secretary
Jill Jene Ph.D Vice President, Business Development
You’re viewing 3 of 13 executive team members. Get the full list »

PDL Biopharma Board Members (8)

Name Representing Role Since
David Gryska Self Board Member 000 0000
You’re viewing 1 of 8 board members. Get the full list »

PDL Biopharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PDL Biopharma Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 10-Jun-2019 0000 0000 Drug Discovery
000000 11-Apr-2019 0000 0000 Drug Discovery 000000000
00000 000000 22-Jul-2016 0000000000 Pharmaceuticals 000000000
00000 000000 06-Jul-2016 000000000 00000 Pharmaceuticals 0000 0000
Axogen 14-Nov-2014 PIPE 000.00 Surgical Devices
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

PDL Biopharma Subsidiaries (1)

Company Name Industry Location Founded
00000 000000 000 Distributors/Wholesale Boston, MA 0000
To view PDL Biopharma’s complete subsidiaries history, request access »

PDL Biopharma Exits (4)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000 22-Jul-2016 000000000000000000 Completed
  • 2 buyers
00000 000000 06-Jul-2016 000000000 00000 Completed
  • 000 000000000
000000 14-Nov-2014 0000 000.00 Completed
  • 2 buyers
Avinger 22-Apr-2013 Mezzanine 0000 Completed
To view PDL Biopharma’s complete exits history, request access »